Treatment of idiopathic/hereditary pulmonary arterial hypertension

Journal of Cardiology

Volumn 64, Issue 4, 2014, Pages 243-249

  Matsubara, Hiromi ^a   Ogawa, Aiko ^a  

^a NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Pulmonary hypertension; Right ventricle; Survival

Indexed keywords

AMBRISENTAN; BOSENTAN; PROSTACYCLIN; RIOCIGUAT; SILDENAFIL; TADALAFIL; TREPROSTINIL; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOPULMONARY EXERCISE TEST; ECHOCARDIOGRAPHY; EXERCISE; HEART FUNCTION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LONG TERM SURVIVAL; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RESPIRATORY FUNCTION; REVIEW; VASODILATATION; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HEART VENTRICLE REMODELING; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84926249782     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.06.009     Document Type: Review

References (41)

1. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., Kernis J.T., Levy P.S., Pietra G.G., Reid L.M., Reeves J.T., Rich S., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
2. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaïci A., Weitzenblum E., Cordier J.F., Chabot F., Dromer C., Pison C., Reynaud-Gaubert M., Haloun A., Laurent M., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
3. Krowka M.J., Miller D.P., Barst R.J., Taichman D., Dweik R.A., Badesch D.B., McGoon M.D. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012, 141:906-915.
4. Barst R.J., Gibbs J.S., Ghofrani H.A., Hoeper M.M., McLaughlin V.V., Rubin L.J., Sitbon O., Tapson V.F., Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S78-S84.
5. Benza R.L., Miller D.P., Gomberg-Maitland M., Frantz R.P., Foreman A.J., Coffey C.S., Frost A., Barst R.J., Badesch D.B., Elliott C.G., Liou T.G., McGoon M.D. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122:164-172.
6. Nickel N., Golpon H., Greer M., Knudsen L., Olsson K., Westerkamp V., Welte T., Hoeper M.M. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012, 39:589-596.
7. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., Nakanishi N., Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487-492.
8. Deboeck G., Scoditti C., Huez S., Vachiery J.L., Lamotte M., Sharples L., Melot C., Naeije R. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012, 40:1410-1419.
9. Hoeper M.M., Pletz M.W., Golpon H., Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007, 29:944-950.
10. Wensel R., Opitz C.F., Anker S.D., Winkler J., Hoffken G., Kleber F.X., Sharma R., Hummel M., Hetzer R., Ewert R. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002, 106:319-324.
11. Fijalkowska A., Kurzyna M., Torbicki A., Szewczyk G., Florczyk M., Pruszczyk P., Szturmowicz M. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129:1313-1321.
12. Nagaya N., Uematsu M., Satoh T., Kyotani S., Sakamaki F., Nakanishi N., Yamagishi M., Kunieda T., Miyatake K. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:487-492.
13. Raymond R.J., Hinderliter A.L., Willis P.W., Ralph D., Caldwell E.J., Williams W., Ettinger N.A., Hill N.S., Summer W.R., de Boisblanc B., Schwartz T., Koch G., Clayton L.M., Jöbsis M.M., Crow J.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002, 39:1214-1219.
14. Forfia P.R., Fisher M.R., Mathai S.C., Housten-Harris T., Hemnes A.R., Borlaug B.A., Chamera E., Corretti M.C., Champion H.C., Abraham T.P., Girgis R.E., Hassoun P.M. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174:1034-1041.
15. van Wolferen S.A., Marcus J.T., Boonstra A., Marques K.M., Bronzwaer J.G., Spreeuwenberg M.D., Postmus P.E., Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007, 28:1250-1257.
16. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., Rubin L.J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
17. Galie N., Badesch D., Oudiz R., Simonneau G., McGoon M.D., Keogh A.M., Frost A.E., Zwicke D., Naeije R., Shapiro S., Olschewski H., Rubin L.J. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46:529-535.
18. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group.
19. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Shapiro S., White R.J., Chan M., Beardsworth A., Frumkin L., Barst R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.
20. Ghofrani H.A., Galie N., Grimminger F., Grunig E., Humbert M., Jing Z.C., Keogh A.M., Langleben D., Kilama M.O., Fritsch A., Neuser D., Rubin L.J. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340. PATENT-1 Study Group.
21. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., Keogh A., Oudiz R., Frost A., Blackburn S.D., Crow J.W., Rubin L.J., Treprostinil Study Group Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
22. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., Brundage B.H., Koerner S.K., Langleben D., Keller C.A., Murali S., Uretsky B.F., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-301.
23. Vonk-Noordegraaf A., Haddad F., Chin K.M., Forfia P.R., Kawut S.M., Lumens J., Naeije R., Newman J., Oudiz R.J., Provencher S., Torbicki A., Voelkel N.F., Hassoun P.M. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013, 62:D22-D33.
24. McLaughlin V.V., Gaine S.P., Howard L.S., Leuchte H.H., Mathier M.A., Mehta S., Palazzini M., Park M.H., Tapson V.F., Sitbon O. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013, 62:D73-D81.
25. Provencher S., Herve P., Jais X., Lebrec D., Humbert M., Simonneau G., Sitbon O. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006, 130:120-126.
26. Galie N., Corris P.A., Frost A., Girgis R.E., Granton J., Jing Z.C., Klepetko W., McGoon M.D., McLaughlin V.V., Preston I.R., Rubin L.J., Sandoval J., Seeger W., Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62:D60-D72.
27. Suga H. Cardiac energetics: from Emax to pressure-volume area. Clin Exp Pharmacol Physiol 2003, 30:580-585.
28. Sunagawa K., Maughan W.L., Sagawa K. Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle. Circ Res 1985, 56:586-595.
29. van der Velde E.T., Burkhoff D., Steendijk P., Karsdon J., Sagawa K., Baan J. Nonlinearity and load sensitivity of end-systolic pressure-volume relation of canine left ventricle in vivo. Circulation 1991, 83:315-327.
30. Kuehne T., Yilmaz S., Steendijk P., Moore P., Groenink M., Saaed M., Weber O., Higgins C.B., Ewert P., Fleck E., Nagel E., Schulze-Neick I., Lange P. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 2004, 110:2010-2016.
31. Overbeek M.J., Lankhaar J.W., Westerhof N., Voskuyl A.E., Boonstra A., Bronzwaer J.G., Marques K.M., Smit E.F., Dijkmans B.A., Vonk-Noordegraaf A. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008, 31:1160-1166.
32. Kerbaul F., Brimioulle S., Rondelet B., Dewachter C., Hubloue I., Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007, 175:846-850.
33. Savarese G., Paolillo S., Costanzo P., D'Amore C., Cecere M., Losco T., Musella F., Gargiulo P., Marciano C., Perrone-Filardi P. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012, 60:1192-1201.
34. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., Rainisio M., Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
35. Yung D., Widlitz A.C., Rosenzweig E.B., Kerstein D., Maislin G., Barst R.J. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004, 110:660-665.
36. Badesch D.B., Raskob G.E., Elliott C.G., Krichman A.M., Farber H.W., Frost A.E., Barst R.J., Benza R.L., Liou T.G., Turner M., Giles S., Feldkircher K., Miller D.P., McGoon M.D. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
37. Birukov K.G. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009, 11:1651-1667.
38. Deb S., Yun J., Burton N., Omron E., Thurber J., Nathan S.D. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest 2006, 130:214-217.
39. Levy N.T., Liapis H., Eisenberg P.R., Botney M.D., Trulock E.P. Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation. J Heart Lung Transplant 2001, 20:381-384.
40. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
41. Ogawa A., Ejiri K., Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014, (February). [Epub ahead of print].